Gilead Moving Forward On Combo HIV Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead expects a deal "shortly" with Bristol-Myers Squibb and Merck to create a fixed-dose combination of Viread, Emtriva and Sustiva
You may also be interested in...
GSK, Boehringer Ingelheim Discussing Co-Packaged Combivir/Viramune
The companies have signed a “letter of intent” and are talking to FDA about NDA submission requirements. The agreement may test how quickly the agency can approve co-packaged HIV therapies, and how easy it is for manufacturers to negotiate deals.
GSK, Boehringer Ingelheim Discussing Co-Packaged Combivir/Viramune
The companies have signed a “letter of intent” and are talking to FDA about NDA submission requirements. The agreement may test how quickly the agency can approve co-packaged HIV therapies, and how easy it is for manufacturers to negotiate deals.
Merck, Bristol, Gilead Are In Discussions For Combo HIV Therapy
Merck, Bristol-Myers Squibb, and Gilead are in discussion to develop a co-packaged version of three different AIDS drugs for use in the developing world